Executives
-
Galvin RoyPresident, Global Plasma & BC -
Miller Laurie A.SVP, Human Resources
-
Simon, ChristopherPresident & CEO
-
Strong Stewart WPresident, Global Hospital
-
Lingamneni AnilaEVP, Chief Technology Officer
-
Llorens JosepEVP, Global Manufacturing
-
Basil Michelle LEVP and General Counsel
-
Maunsell Farris MaryanneVP, Chief Accounting Officer
-
Darecca JamesEVP, Chief Financial Officer
?
Llorens Josep
EVP, Global Manufacturing
Haemonetics Corporation
US, Boston [HQ]
CIK
1750812
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
35,450
Price per Share :
$73.49
Equivalence :
$2,605,220.50
Transaction History
-
A35,450 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/28/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.
-
F30,940 Shares After TransactionValue : $2,961,886.20$431,742.30Transaction Date : 05/28/24
-
Footnotes
-
-
Footnotes:#1 Represents shares earned from a performance share unit ("PSU") award granted to the reporting person on May 18, 2021, based on the issuer's total shareholder return relative to that of the companies comprising the S&P MidCap 400 Index for the performance period from May 18, 2021 to May 17, 2024, as certified by the Compensation Committee of the Board of Directors on May 26, 2024.#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain PSUs reported in Table I.
-
S16,350 Shares After TransactionValue : $1,550,307.00Sold $77,942.04Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.#4 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.#5 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
-
F16,030 Shares After TransactionValue : $1,534,551.90$30,633.60Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.#4 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.#5 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
-
A22,297 Shares After TransactionValue : $n/a$0.0Transaction Date : 05/17/24
-
Footnotes
-
-
Footnotes:#1 Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023).#2 This number includes unvested restricted stock units ("RSUs") previously reported.#3 Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.#4 The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.#5 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.